Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Jodi A. Kagihara"'
Autor:
Anna R. Schreiber, Jodi A. Kagihara, Bradley R. Corr, S. Lindsey Davis, Christopher Lieu, Sunnie S. Kim, Antonio Jimeno, D. Ross Camidge, Jud Williams, Amy M. Heim, Anne Martin, John A. DeMattei, Nisha Holay, Todd A. Triplett, S. Gail Eckhardt, Kevin Litwiler, James Winkler, Anthony D. Piscopio, Jennifer R. Diamond
Publikováno v:
Cancers, Vol 16, Iss 1, p 91 (2023)
(1) Background: Histone deacetylases (HDACs) play a critical role in epigenetic signaling in cancer; however, available HDAC inhibitors have limited therapeutic windows and suboptimal pharmacokinetics (PK). This first-in-human phase I dose escalation
Externí odkaz:
https://doaj.org/article/451d3f14506a4c3c96f07402e100bfa1
Autor:
Anna R. Schreiber, Jodi A. Kagihara, Jennifer A. Weiss, Andrew Nicklawsky, Dexiang Gao, Virginia F. Borges, Peter Kabos, Jennifer R. Diamond
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundImmuno-oncology (IO) agents have demonstrated efficacy across many tumor types and have led to change in standard of care. In breast cancer, atezolizumab and pembrolizumab were recently FDA-approved in combination with chemotherapy specific
Externí odkaz:
https://doaj.org/article/7cad4709ed834477a9de7a3da6866490
Autor:
Jodi A. Kagihara, Elizabeth Molina, Lavanya Kondapalli, Peter Kabos, Jennifer R. Diamond, Cathy J. Bradley, Megan Eguchi, Elisabeth Meyer, Christine M. Fisher, Anna R Schreiber
Publikováno v:
Breast Cancer Research and Treatment
Purpose Adjuvant chemotherapy reduces recurrence in early-stage triple-negative breast cancer (TNBC). However, data are lacking evaluating anthracycline + taxane (ATAX) versus taxane-based (TAX) chemotherapy in older women with node-negative TNBC, as
Publikováno v:
Curr Breast Cancer Rep
PURPOSE OF REVIEW: In this review, we discuss targets of interest in Triple-negative breast cancer (TNBC), approved targeted agents and the results of the clinical trials that led to their approval. Additionally, we review ongoing clinical trials eva
Publikováno v:
Journal of Breast Cancer
Paraneoplastic neurologic diseases (PND) are rare but can occur in patients with common malignancies including breast cancer. In patients with hormone receptor (HR)-negative human epidermal growth factor receptor 2 (HER2)-positive breast cancer, PND
Autor:
Stephen Leong, S.G. Eckhardt, Jodi A. Kagihara, Virginia F. Borges, Jennifer A Weiss, Dexiang Gao, Andrew Nicklawsky, Jennifer R. Diamond, Anthony D. Elias, Peter Kabos, Christine M. Fisher, Sarah Lindsey Davis
Publikováno v:
Cancer Medicine
Patients with metastatic breast cancer (MBC) refractory to standard of care therapies have a poor prognosis. The purpose of this study was to assess patient characteristics and clinical outcomes for patients with MBC treated on phase I clinical trial
Publikováno v:
Journal of the National Comprehensive Cancer Network. 18:CLO20-060
Autor:
Dexiang Gao, Jennifer A Weiss, Anna R Schreiber, Andrew Nicklawsky, Jennifer R. Diamond, Virginia F. Borges, Jodi A. Kagihara, Peter Kabos
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology, Vol 11 (2021)
BackgroundImmuno-oncology (IO) agents have demonstrated efficacy across many tumor types and have led to change in standard of care. In breast cancer, atezolizumab and pembrolizumab were recently FDA-approved in combination with chemotherapy specific
Autor:
Virginia F. Borges, Peter Kabos, Ericson Stoen, Elena Shagisultanova, Andrew Nicklawsky, Jennifer R. Diamond, Christine M. Fisher, Jodi A. Kagihara
Publikováno v:
Breast Cancer Research and Treatment
Purpose Adjuvant pertuzumab and neratinib are independently FDA-approved for treatment of early-stage HER2-positive breast cancer in combination with or following trastuzumab for one year, respectively. Both agents reduce the risk of recurrence; howe
Publikováno v:
Expert Rev Precis Med Drug Dev
INTRODUCTION: Breast cancer is the most common malignancy in women in the United States and triple-negative breast cancer (TNBC) accounts for 15–20%. The standard of care for metastatic TNBC has been limited to cytotoxic chemotherapy with modest ef